Stimulants and cardiovascular safety in adults

For decades the conversation about stimulant cardiovascular risk was muddled, with primary care doctors being more cautious than the data warranted and psychiatrists being maybe a little too dismissive. The 2025 large-scale analyses cleaned up the picture significantly. The short version: for most adults without pre-existing serious heart disease, stimulants are safer than the field has been treating them. For a specific subset of adults with real cardiac risk factors, the workup before prescribing matters more than the field used to admit.

The stimulants used for ADHD in adults are mostly methylphenidate-based (Ritalin, Concerta, Focalin) and amphetamine-based (Adderall, Vyvanse, Mydayis). Vyvanse, for the record, is the one I’m personally on and the one I tend to favor when the patient hasn’t already landed on something else for their own reasons. The medications raise blood pressure on average by 2 to 4 mmHg and heart rate by 3 to 6 beats per minute. Those aren’t big changes in absolute terms. They’re real, and they sustain over years on the medication.

What the 2025 data actually showed

The Swedish national registry studies and the 2025 network meta-analysis that pulled together more than 100 trials (Farhat et al. 2025) came to consistent conclusions.

One: in adults without significant pre-existing cardiovascular disease, stimulant use doesn’t increase the rate of heart attacks, strokes, or sudden cardiac death over years of follow-up. The effect size for any cardiac event is small and not consistently in the bad direction. The field had been overcautious about this for a long time, and the 2025 data is the cleanest version of “it’s mostly fine” we’ve had.

Two: in adults with significant pre-existing cardiovascular disease, particularly uncontrolled hypertension, recent heart attack, certain arrhythmias, or structural heart disease, the picture is genuinely different. The relative risk of bad outcomes goes up, sometimes substantially. This is where the cardiac caveat lives, and the honest version of the conversation is that anyone on multiple cardiac medications, anyone with recent cardiac events, anyone whose first-time-on-a-stimulant conversation is happening at 60 with multiple risk factors, is in a real conversation about trade-offs, not a rubber-stamp prescription. Any prescriber who pretends stimulants are completely safe in cardiac patients is a damn liar.

Three: the modest sustained increase in blood pressure on stimulants does, over years on the medication, contribute to small increases in cardiovascular risk that show up at the population level even when the individual contribution is small. For one patient on Vyvanse for ten years, the contribution is modest. For everyone on stimulants long-term, it adds up to something the field has to keep an eye on.

Four: in older adults (over 60 or so), the calculus shifts more toward caution, partly because the baseline cardiac risk is higher and partly because the first-time-on-a-stimulant-at-60 conversation is genuinely a different conversation than the same medication starting at 30.

Who needs the workup before starting stimulants

Old approach: everybody, with an EKG and a lot of hand-wringing whether or not the patient had any actual risk factors.

2025 approach: targeted screening based on what’s actually present in the picture.

Family history of sudden cardiac death before age 50 means a real cardiac evaluation before anyone writes a script. EKG, possibly echo, often a cardiology consult. This is the family-history red flag and it doesn’t get talked around.

Personal history of chest pain on exertion, unexplained passing out, palpitations with exertion, or known structural heart disease means cardiology evaluation first. Same logic.

Hypertension that isn’t controlled (blood pressure consistently above 140/90) means controlling the blood pressure first, then having the stimulant conversation. Starting a stimulant on top of uncontrolled hypertension is the move nobody should be making in 2026 with the data we have.

Age over 55 with multiple cardiovascular risk factors (smoking, obesity, diabetes, family history) means at minimum an EKG before starting, sometimes more depending on what the EKG shows.

Otherwise healthy adult with normal blood pressure and no concerning family history: a careful history, a recent blood pressure check, an EKG if there hasn’t been one in a while. That’s usually enough. The “everybody gets a cardiology consult and an echo before Adderall” version of caution was overkill for most patients and the 2025 data made that clearer.

What gets monitored on stimulants

Blood pressure at every visit. Heart rate. Any new chest pain, palpitations, or unusual exertion fatigue. If blood pressure climbs above 140/90 or so on a stable stimulant dose, the move is either treating the blood pressure or adjusting the stimulant, not ignoring it and hoping it sorts itself out.

For adults with borderline blood pressure, sometimes the right move is using clonidine or guanfacine (a class of medications that help with ADHD and also lower blood pressure) as an add-on. They help the ADHD picture, they bring blood pressure down, and the net cardiac effect on the patient can be neutral or actually favorable. Two-fer that doesn’t get used as often as it could.

What “controlled” hypertension means

Some patients hear “you can’t have stimulants if you have hypertension” and assume the conversation is over. That’s not quite right. If blood pressure is well-controlled on medication, stimulants are usually still on the table. The control is what matters, not the diagnosis. Coordinate with the primary care doctor or cardiologist. Watch the numbers. Adjust if things drift. The medication isn’t the enemy of cardiac health, uncontrolled blood pressure is.

The pattern this is rearranging

The kind of guy this conversation is changing the most is somebody in his mid-forties who’s suspected he has ADHD for years, whose kid was diagnosed and treated successfully and made him look harder at his own picture, who meets criteria clearly on evaluation and also has untreated mild hypertension (138/88 consistently on multiple readings) and a family history of early heart attacks on his father’s side. Five years ago, that picture would have made the prescriber more anxious about Vyvanse than the data actually supported. The 2025 version of the conversation is cleaner: address the blood pressure first with a primary care visit and an ACE inhibitor, get the numbers down into the controlled range, get a normal EKG, then start the stimulant at a conservative dose with active monitoring. Blood pressure stays controlled, the ADHD picture improves dramatically, the cardiologist signs off. A year in, everything is working across both fronts and the patient’s quality of life at work is noticeably better than it’s been.

The change isn’t that the medication is different. The change is that the conversation about what to do before, during, and on top of the prescription got cleaner and less reflexive in both directions.

The control is what matters, not the diagnosis. If blood pressure is well-controlled on medication, you can have stimulants. We coordinate. We watch.

The conversation with a newly diagnosed adult

For most adults under 50 with no family history of early cardiac events and normal blood pressure, the cardiovascular risk of stimulants is small and well-characterized. For most adults over 55 or with real risk factors, the workup matters and the active monitoring during treatment matters, and skipping either one is the move that turns a safe medication into a problem. For adults with active significant heart disease, the right move is usually a non-stimulant option (atomoxetine, viloxazine, sometimes clonidine or guanfacine alone), and that’s not a tragedy because those medications work too, just differently.

What’s not acceptable anymore is either reflexive refusal of stimulants in adults because of vague cardiac fears, or reflexive prescribing without basic cardiac screening. The middle path is well-supported by the 2025 data and is the version of the conversation that most reasonable prescribers should be having.

Where the autonomy stance lands

The decision to start a stimulant is the patient’s. My job is to be honest about what the data shows, what your specific cardiac picture looks like, what the workup is going to involve, and what we’d be watching for once you’re on the medication. I’m a provider, not a parent. If you’ve heard the risks (including the honest version of the cardiac caveat, which is that this isn’t no-risk for everyone) and you want the prescription, you get the prescription. I’m opinionated about how it should be done, not a gatekeeper standing in the way.

What’s nice to hear, because most of this post has been about screening and monitoring and risk factors, is that for the adult who actually has ADHD and tolerates the medication well, a stimulant is one of the most consistently effective medications in psychiatry. The hit rate is high. The change shows up fast. The improvement is usually noticeable across work, relationships, and what runs the patient’s day, which is most of what people actually want from a medication. The cardiac monitoring is the price of doing it right, not a reason to avoid it.

Bottom line

For most adults with ADHD, stimulants are safer than the field has been treating them, and the reflexive caution about prescribing them in average patients should stop. For a specific subset with real cardiac risk factors, the workup before starting matters and should actually happen. Annual blood pressure and pulse monitoring on stimulants should be routine, not optional. The 2025 data didn’t change the medications. It changed the way the conversation about them should be calibrated. Less hand-wringing about average patients. More actual attention to the patients who genuinely need it.

Sources

1. Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(11):e2243597. PMID 36416824.
2. Zhang L, Li L, Andell P, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2024;81(2):178-187. PMID 37991787.
3. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-2683. PMID 22161946.
4. Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12(5):355-365. PMID 40203844.